Small molecule inhibitors of cell signaling: Novel future therapeutics for asthma and chronic obstructive pulmonary diseases

Current Opinion in Investigational Drugs

Volumn 4, Issue 5, 2003, Pages 544-551

  Blease, Kate ^a   Raymon, Heather K ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Airway remodeling; Asthma; COPD; Intracellular signaling; MAP kinase inhibitors

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CILOMILAST; CORTICOSTEROID; MITOGEN ACTIVATED PROTEIN KINASE; MONTELUKAST; NVP QAB 205AA; PHOSPHODIESTERASE IV INHIBITOR; RESPIRATORY TRACT AGENT; ROFLUMILAST; ROLIPRAM; SP 100030; SPC 105; STAT6 PROTEIN INHIBITOR; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SYK INHIBITOR; SYNAPTOPHYSIN; SYNAPTOPHYSIN INHIBITOR; THEOPHYLLINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

AIRWAY CONSTRICTION; AIRWAY OBSTRUCTION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; EPIDEMIC; HEALTH CARE NEED; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NAUSEA AND VOMITING; NONHUMAN; PATHOGENESIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; ASTHMA; DRUG DELIVERY SYSTEMS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037504182     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Postma DS, Kerstjens HA: Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 158(5 Pt 3):S187-S192.
2. Boulet LP, Chakir J, Dube J, Laprise C, Boutet M, Laviolette M: Airway inflammation and structural changes in airway hyperresponsiveness and asthma: An overview. Can Respir J (1998) 5(1):16-21.
3. Kirby JG, Hargreave FE, Gleich GJ, O'Byrne PM: Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis (1987) 136(2):379-383.
4. Lukacs NW: Role of chemokines in the pathogenesis of asthma. Nat Rev Immunol (2001) 1(2):108-116.
5. Kips JC: Cytokines in asthma. Eur Respir J (2001) 34(Suppl):S24-S33. Comprehensive review describing the role of the major cytokines involved in the pathogenesis of asthma.
6. Busse WW, Lemanske RF Jr: Asthma. N Engl J Med (2001) 344(5):350-362.
7. Cosio MG, Hale KA, Niewoehner DE: Morphological and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis (1980) 122(2):265-271.
8. Saetta M, Finkelstein R, Cosio MG: Morphological and cellular basis for airflow limitation in smokers. Eur Respir J (1994) 7(8):1505-1515.
9. Barnes PJ: Mechanisms in COPD: Differences from asthma. Chest (2000) 117 (Suppl 2):10-14. Interesting review describing the major pathological differences between asthma and COPD.
10. Rennard S: Inflammation and repair processes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 160 (5 Pt 2):S12-S16.
11. Barnes PJ: Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol (1998) 102(4 Pt 1):531-538.
12. Dent G: Ciclesonide (Byk Gulden). Curr Opin Invest Drugs (2002) 3(1):78-83.
13. Hoag JE, McFadden ER Jr: Long-term effect of cromolyn sodium on nonspecific bronchial hyperresponsiveness: A review. Ann Allergy (1991) 66(1):53-63.
14. Calhoun WJ: Anti-leukotrienes for asthma. Curr Opin Pharmacol (2001) 1(3):230-234.
15. Spina D: Theophylline and PDE4 inhibitors in asthma. Curr Opin Pulm Med (2003) 9(1):57-64.
16. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ: Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol (1996) 118(8):1945-1958.
17. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM: Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol (1999) 56(1):170-174.
18. Torphy TJ: Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med (1998) 157(2):351-370.
19. Barnette MS, Underwood DC: New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med (2000) 6(2):164-169.
20. Giembycz MA: Cilomilast: A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs (2001) 10(7):1361-1379.
21. Reid P: Roflumilast (Altana Pharma). Curr Opin Invest Drugs (2002) 3(8):1165-1170.
22. Barnes PJ, Adcock IM: Transcription factors and asthma. Eur Respir J (1998) 12(1):221-234.
23. Dong C, Davis RJ, Flavell RA: MAP kinases in the immune response. Annu Rev Immunol (2002) 20:55-72.
24. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 298(5600):1911-1912.
25. Escott KJ, Belvisi MG, Birrell MA, Webber SE, Foster ML, Sargent CA: Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat. Br J Pharmacol (2000) 131(2):173-176.
26. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther (2000) 293(1):281-288.
27. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol (2000) 279(5):L895-L902. Demonstrates the beneficial effects of p38 inhibition as a potential for the treatment of COPD.
28. Weston CR, Davis RJ: The JNK signal transduction pathway. Curr Opin Genet Dev (2002) 12(1):14-21.
29. 2-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8+ T cell activation. J Exp Med (2002) 195(7):811-823.
30. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS et al: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA (2001) 98(24):13681-13686. Describes the first small molecule JNK inhibitor used to determine the role of JNK in inflammatory airway disease.
31. Celgene Corp: Celgene Corporation presents preclinical data on the use of novel JNK inhibitor for the treatment of asthma. Press Release (2001) May 23.
32. Hele D: American Thoracic Society - 97th Annual Conference (Part II), San Francisco, CA, USA. IDdb Meeting Report (2001).
33. Hubbard SR, Till JH: Protein tyrosine kinase structure and function. Annu Rev Biochem (2000) 69:373-398.
34. Yanagi S, Inatome R, Takano T, Yamamura H: Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun (2001) 288(3):495-498.
35. Stenton GR, Ulanova M, Dery RE, Merani S, Kim MK, Gilchrist M, Puttagunta L, Musat-Marcu S, James D, Schreiber AD, Befus AD: Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol (2002) 169(2):1028-1036.
36. Hayler J, IeGrand D, Bammerlin H, Cockroft XL, Collingwood S, Mattes H, Menear K, Walker C, Arnold N, Bailey C, Beattig U et al: Novel 2,6-disubstituted purines - The synthesis of potent and selective inhibitors of the protein tyrosine kinase Syk. Drugs Future (2002) 27(Suppl A):P280.
37. lck deficiency on the growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line. Mol Cell Biol (1992) 12(10):4521-4530.
38. Straus DB, Weiss A: Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell (1992) 70(4):585-593.
39. lck. Nature (1992) 357(6374):161-164.
40. Pernis AB, Rothman PB: JAK-STAT signaling in asthma. J Clin Invest (2002) 109(10):1279-1283.
41. Stein RC, Waterfield MD: PI3-kinase inhibition: A target for drug development? Mol Med Today (2000) 6(9):347-357.
42. Condliffe AM, Cadwallader KA, Walker TR, Rintoul RC, Cowburn AS, Chilvers ER: Phosphoinositide 3-kinase: A critical signaling event in pulmonary cells. Respir Res (2000) 1(1):24-29.
43. Huang TJ, Adcock IM, Chung KF: A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. Br J Pharmacol (2001) 134(5):1029-1036.
44. Akimoto T, Numata F, Tamura M, Takata Y, Higashida N, Takashi T, Takeda K, Akira S: Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med (1998) 187(9):1537-1542. Report identifying the key role of STAT6 signaling in eosinophil infiltration into the lungs and airway hyperresponsiveness.
45. Miyata S, Matsuyama T, Kodama T, Nishioka Y, Kuribayashi K, Takeda K, Akira S, Sugita M: STAT6 deficiency in a mouse model of allergen-induced airways inflammation abolishes eosinophilia but induces infiltration of CD8+ T cells. Clin Exp Allergy (1999) 29(1):114-123.
46. Shimoda K, Van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA, Doherty PC et al: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted STAT6 gene. Nature (1996) 380(6575):630-633.
47. Mullings RE, Wilson SJ, Puddicombe SM, Lordan JL, Bucchieri F, Djukanovic R, Howarth PH, Harper S, Holgate ST, Davies DE: Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. J Allergy Clin Immunol (2001) 108(5):832-838.
48. Huang AX, Piper D, Medina J, Cushing T, Daniel C, Elzein E, Huang L, Liu J, McCrea B, McKiney J, Peto C et al: Binding of potent STAT6 inhibitors revealed by crystal structures. ACS (2002) 223:MEDI 79.
49. Robinson DS, Lloyd CM: Asthma: T-bet - A master controller? Curr Biol (2002) 12(9):R322-R324.
50. Ray A, Cohn L: Th2 cells and GATA-3 in asthma: New insights into the regulation of airway inflammation. J Clin Invest (1999) 104(8):985-993.